
News|Articles|November 1, 2012
Vascepa (Icosapent ethyl)
New molecular entity: FDA approved icosapent ethyl (Vascepa, Amarin Pharmaceuticals Ireland Limited), an ethyl ester of eicosapentaenoic acid (EPA), as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves new sunscreen ingredient, first time in 20 years
2
Hospitals facing financial headwinds can't afford to ignore the mounting threats to 340B
3
FDA sets goal date for ophthalmic version of bevacizumab
4
Most blood cancer patients initially denied coverage for oral medications
5
































